JYNTHealthcare · Medical Care FacilitiesThe 4 Wall Street analysts covering The Joint Corp. (United States) hold a median 12-month price target of $9 — +7.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores The Joint Corp. (United States) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JYNT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +7.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Aug 2025 | B. Riley Securities | Maintains | Buy | $20 → $18 |
| 8 Aug 2025 | B. Riley Securities | Maintains | Buy | — |
| 9 May 2025 | Lake Street | Maintains | Buy | — |
| 8 Nov 2024 | Roth MKM | Maintains | Buy | — |
| 6 May 2024 | B. Riley Securities | Maintains | Buy | — |
| 3 May 2024 | Roth MKM | Reiterates | Buy | — |
| 14 Sept 2023 | Roth MKM | Maintains | Buy | — |
| 11 Aug 2023 | Maxim Group | Downgrade | Hold | — |
| 11 Aug 2023 | Roth MKM | Maintains | Buy | — |
| 13 Mar 2023 | DA Davidson | Upgrade | Neutral | — |
| 8 Aug 2022 | DA Davidson | Maintains | Underperform | — |
| 5 Aug 2022 | B. Riley Securities | Upgrade | Buy | — |
| 5 Aug 2022 | Maxim Group | Upgrade | Buy | — |
| 10 May 2022 | DA Davidson | Downgrade | Underperform | — |
| 9 May 2022 | DA Davidson | Downgrade | Underperform | — |
| 6 May 2022 | Craig-Hallum | Downgrade | Hold | — |
| 25 Feb 2022 | DA Davidson | Maintains | Buy | — |
| 9 Aug 2021 | DA Davidson | Maintains | Buy | — |
| 6 Aug 2021 | Roth Capital | Maintains | Buy | — |
| 28 June 2021 | Roth Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JYNT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 12% of US stocks
Cheaper than 53% of US stocks
Cheaper than 15% of US stocks
Cheaper than 13% of US stocks
Higher than 62% of US stocks
Higher than 96% of US stocks
Higher than 93% of US stocks
Higher than 51% of US stocks
Higher than 63% of US stocks
Higher than 65% of US stocks
Higher than 61% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own The Joint Corp. (United States) — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of The Joint Corp.'s Q2 2026 earnings call. The item reports the availability of the call's full discussion and commentary.
Why it matters — The transcript gives JYNT watchers direct access to management's own account of the quarter's results and outlook.
The Joint Corp. reported second-quarter results that showed progress in its shift toward a capital-light, pure-play franchisor model. Management also said patient retention improved to its highest level in more than five years.
Why it matters — For JYNT watchers, the reported progress on its franchise-focused strategy and the improvement in patient retention point to the company's operational momentum in its core business.
The Joint Corp. (JYNT) reported a Q2 loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.11 per share. The loss narrowed compared to the $0.06 per share loss reported a year ago.
Why it matters — A JYNT watcher would note that the company's quarterly earnings fell short of analyst expectations, extending a pattern of losses.
The Joint Corp. has been named by Entrepreneur as one of its Top Brands for Multi-Unit Owners for 2026, recognizing the company as a premier growth opportunity for experienced multi-unit and multi-brand investors.
Why it matters — The recognition signals to JYNT watchers that the company's franchise model continues to gain credibility and traction among experienced investors in the healthcare franchise space.
The 4 Wall Street analysts covering The Joint Corp. (United States) have a median 12-month price target of $9, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering The Joint Corp. (United States), 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Joint Corp. (United States) 88 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, The Joint Corp. (United States) ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +7.3% from the last close, and Ticker Nerd's factor model ranks The Joint Corp. (United States) 88 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Joint Corp. (United States) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JYNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.
The Joint Corp. (United States) returned -19.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
The Joint Corp. is a key player in the chiropractic care sector, focusing on providing accessible and affordable chiropractic services through its network of clinics.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "The Joint Corp. (JYNT) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of The Joint Corp.'s Q2 2026 earnings call. The item reports the availability of the call's full discussion and commentary.
The Joint Corp. is a key player in the chiropractic care sector, focusing on providing accessible and affordable chiropractic services through its network of clinics. The company operates a franchise model, expanding its reach across various regions to deliver routine treatment without the need for insurance or appointments. Specializing in back, neck, and osteopathic health, The Joint Corp. caters to the growing demand for non-invasive, role-altering alternative to traditional medicine. A major feature of The Joint Corp. is its innovative approach to healthcare delivery, emphasizing convenience and customer-centricity in its service offerings. With a subscription-based model, the company supports consistent revenue streams while ensuring continuous care for its clients. Impacting the healthcare and wellness industries, The Joint Corp.'s presence underscores the increasing consumer inclination towards holistic and preventive health solutions. In the financial market, The Joint Corp. stands out by leveraging its unique position in a niche healthcare segment, contributing to its recognition as an emerging leader in chiropractic care. Its expanding footprint and consumer-friendly practices have made it a notable entity in the healthcare services market.
CEO Mr. Sanjiv Razdan · 202 employees · United States · https://www.thejoint.com